More safety data is needed before an experimental flu vaccine made inside insect cells should be approved, a US federal advisory committee said yesterday.
A US Food and Drug Administration (FDA) panel voted 6-to-5 that Protein Sciences, a vaccine company based in Meriden, Connecticut, hadn’t proven that its FluBlok vaccine was safe enough to enter mass production. Nine of the 11 panellists, however, said the shot was effective in adults aged 18 to 49, although the vaccine did not appear to work as well in older patients.
Human embryonic stem cells could be one step closer to the clinic. Santa Monica, California-based Advanced Cell Technology (ACT) announced today that it has applied to US regulators to launch a new clinical trial aimed at reversing vision loss with retinal cells recreated from embryonic stem (ES) cells.
The main taxpayer-backed agency that funds health-related research needs to pay more heed to ethical lapses and financial conflicts of interest, say more than 100 scientists, physicians, medical ethicists, journal editors and others.
Two blockbuster cholesterol drugs are not as effective at unclogging arteries as a cheap vitamin for patients already taking cholesterol-lowering statins.